Safety and efficacy of generic daclatasvir-sofosbuvir as a pan genotypic regimen for HCV-infected patients in Bandung, Indonesia

被引：0
|
作者：
Bestari, Muhammad Begawan [1 ]
Nugraha, Eka Surya [1 ]
Abdurachman, Siti Aminah [1 ]
机构：
[1] Univ Padjadjaran, Hasan Sadikin Gen Hosp, Dept Internal Med GI Hepatol, Bandung, Indonesia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2018年 / 33卷
关键词：
hepatitis C; pan genotypic; treatment; sofosbuvir; daclatasvir;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OE-0189 (P
引用
收藏
页码：443 / 443
页数：1
相关论文
共 50 条
  • [41] Improved virological outcomes and excellent safety profile in genotype 3 HCV-infected cirrhotic patients after an extended 24-weeks course of daclatasvir, sofosbuvir plus ribavirin: insights froma real-life multicenter study
    Lionetti, R.
    Lenci, I.
    Siciliano, M.
    Pompili, M.
    Comandini, U. V.
    Milana, M.
    Taibi, C.
    Montalbano, M.
    Garbuglia, A. R.
    Begini, P.
    Imperatrice, B.
    Angelico, M.
    D'Offizi, G.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S731 - S731
  • [42] MODELING THE COST-EFFECTIVENESS OF THE ALL ORAL, DIRECT-ACTING ANTIVIRAL REGIMEN DACLATASVIR PLUS SOFOSBUVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS (HCV) AND HIV
    McEwan, P.
    Ward, T.
    Webster, S.
    Kalsekar, A.
    Brenner, M.
    Yuan, Y.
    VALUE IN HEALTH, 2015, 18 (07) : A628 - A628
  • [43] Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
    Hiromitsu Kumada
    Tsunamasa Watanabe
    Fumitaka Suzuki
    Kenji Ikeda
    Ken Sato
    Hidenori Toyoda
    Masanori Atsukawa
    Akio Ido
    Akinobu Takaki
    Nobuyuki Enomoto
    Koji Kato
    Katia Alves
    Margaret Burroughs
    Rebecca Redman
    David Pugatch
    Tami J. Pilot-Matias
    Preethi Krishnan
    Rajneet K. Oberoi
    Wangang Xie
    Kazuaki Chayama
    Journal of Gastroenterology, 2018, 53 : 566 - 575
  • [44] SAFETY & EFFICACY OF COMBINATION THERAPY WITH OMBITASVIR, PARITAPREVIR & RITONAVIR PLUS DASABUVIR IN HCV-INFECTED PATIENTS WITH CHRONIC KIDNEY DISEASE RECEIVING HEMODIALYSIS
    Lazarou, Dimitrios
    Xynotroulas, Ioannis
    Provatopoulou, Simella
    Vogiatzi, Apostolia
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [45] Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
    Kumada, Hiromitsu
    Watanabe, Tsunamasa
    Suzuki, Fumitaka
    Ikeda, Kenji
    Sato, Ken
    Toyoda, Hidenori
    Atsukawa, Masanori
    Ido, Akio
    Takaki, Akinobu
    Enomoto, Nobuyuki
    Kato, Koji
    Alves, Katia
    Burroughs, Margaret
    Redman, Rebecca
    Pugatch, David
    Pilot-Matias, Tami J.
    Krishnan, Preethi
    Oberoi, Rajneet K.
    Xie, Wangang
    Chayama, Kazuaki
    JOURNAL OF GASTROENTEROLOGY, 2018, 53 (04) : 566 - 575
  • [46] Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV
    Zeng, Q. -L.
    Li, C. -X.
    Zhang, D. -W.
    Li, W.
    Xu, G. -H.
    Yu, Z. -J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (07) : 842 - 843
  • [47] Real-World Safety and Efficacy of Ribavirin-free regimen of Ombitasvir/Paritaprevir/Ritonavir for dialysis patients infected with HCV
    Derbala, Moutaz
    Chandra, Prem
    Mohiuddin, Syed A.
    Amer, Aliaa
    Elsayad, Elham
    Al-Ali, Fadwa S.
    Khater, Iman I.
    HEPATOLOGY, 2017, 66 : 576A - 576A
  • [48] Daclatasvir, Simeprevir and Ribavirin as a new IFN-free triple regimen for HCV recurrence after liver transplantation: First results of safety and efficacy in 6 patients
    Papadopoulos-Koehn, Angela
    Timm, Joerg
    Canbay, Ali
    Jochum, Christoph
    Gerken, Guido
    Herzer, Kerstin
    HEPATOLOGY, 2014, 60 : 697A - 697A
  • [49] DACLATASVIR, SIMEPREVIR AND RIBAVIRIN AS A NEW IFN-FREE TRIPLE REGIMEN FOR HCV RECURRENCE AFTER LIVER TRANSPLANTATION: FIRST RESULTS OF SAFETY AND EFFICACY IN 6 PATIENTS
    Papadopoulos-Koehn, A.
    Timm, J.
    Canbay, A.
    Jochum, C.
    Paul, A.
    Gerken, G.
    Herzer, K.
    TRANSPLANT INTERNATIONAL, 2014, 27 : 19 - 19
  • [50] EFFICACY AND SAFETY OF PAN-GENOTYPIC SOFOSBUVIR AND VELPATASVIR IN PATIENTS WITH HEPATITIS C REINFECTION FOLLOWING ATTAINMENT OF SUSTAINED VIROLOGICAL RESPONSE WITH NS5A INHIBITORS
    De, Arka
    Bhagat, Naveen
    Charak, Swati
    Kaur, Rajwant
    Kaur, Talwinder
    Rathi, Sahaj
    Verma, Nipun
    Premkumar, Madhumita
    Taneja, Sunil
    Duseja, Ajay
    Singh, Virendra
    GASTROENTEROLOGY, 2022, 162 (07) : S1153 - S1153
12345